Keywords
Eligibility Determination ×
Lymphoma, Mantle-Cell ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

22 Search results.

Eligibility Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma NCT01693614

- 12/1/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL; ODM derived from: https://clinicaltrials.gov/show/NCT01693614

Eligibility Lymphoma, Mantle-Cell NCT02413489

- 5/2/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02413489

Eligibility Lymphoma, Mantle-Cell NCT02419560

- 4/30/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL; ODM derived from: https://clinicaltrials.gov/show/NCT02419560

Eligibility Non-Hodgkin's Lymphoma (NHL) NCT01180049

- 1/8/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01180049

Eligibility Mantle Cell Lymphoma NCT00541424

- 6/14/18 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00541424

Eligibility Mantle Cell Lymphoma NCT00737529

- 6/14/18 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial; ODM derived from: https://clinicaltrials.gov/show/NCT00737529

Eligibility Mantle Cell Lymphoma NCT00963534

- 6/14/18 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00963534

Eligibility Lymphoma, Mantle-Cell NCT00871546

- 6/4/18 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715); ODM derived from: https://clinicaltrials.gov/show/NCT00871546

Eligibility Contiguous Stage II Mantle Cell Lymphoma NCT00433537

- 1/11/18 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00433537

Eligibility Non-Hodgkin's Lymphoma NCT00612183

- 6/2/17 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00612183

Eligibility Mantle Cell Lymphoma NCT00505232

- 5/3/17 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02); ODM derived from: https://clinicaltrials.gov/show/NCT00505232

Eligibility Lymphoma NCT00740415

- 4/7/17 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Criteria
Rituximab, Bortezomib, Doxorubicin, Dexamethasone, and Chlorambucil Patients With Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00740415